Stephen Baker Selected Research

Ciprofloxacin (Cipro)

1/2021	Inhibitory Concentrations of Ciprofloxacin Induce an Adaptive Response Promoting the Intracellular Survival of Salmonella enterica Serovar Typhimurium.
1/2019	Endemic fluoroquinolone-resistant Salmonellaenterica serovar Kentucky ST198 in northern India.
3/2016	Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections.
1/2016	South Asia as a Reservoir for the Global Spread of Ciprofloxacin-Resistant Shigella sonnei: A Cross-Sectional Study.
10/2014	Typhoid fever in Fiji: a reversible plague?
2/2014	Risk factors for the development of severe typhoid fever in Vietnam.
12/2012	Enteric fever in Cambodian children is dominated by multidrug-resistant H58 Salmonella enterica serovar Typhi with intermediate susceptibility to ciprofloxacin.
5/2012	Highly resistant Salmonella enterica serovar Typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever.
8/2011	A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children.
12/2010	Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen Baker Research Topics

Disease

73	Typhoid Fever (Typhoid) 12/2021 - 05/2010
39	Infections 01/2022 - 03/2004
11	Fever (Fevers) 12/2019 - 06/2011
10	Bacillary Dysentery (Shigellosis) 01/2022 - 08/2011
6	Sepsis (Septicemia) 06/2022 - 03/2016
6	Wounds and Injuries (Trauma) 12/2019 - 08/2006
4	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 01/2012
4	Salmonella Infections (Salmonellosis) 01/2021 - 03/2016
4	Diarrhea 01/2018 - 01/2013
3	COVID-19 01/2022 - 01/2020
3	Neoplasms (Cancer) 01/2021 - 10/2010
3	Bacteremia 01/2017 - 01/2013
2	Critical Illness (Critically Ill) 01/2022 - 03/2020
2	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2020
2	Mycoses (Diseases, Fungus) 01/2021 - 01/2019
2	Dengue (Dengue Fever) 07/2020 - 10/2016
2	Body Weight (Weight, Body) 01/2019 - 10/2018
2	Insulin Resistance 01/2019 - 09/2007
2	Dysentery 01/2018 - 06/2010
2	Pain (Aches) 02/2017 - 01/2017
2	Paratyphoid Fever 01/2017 - 03/2014
2	Malaria 03/2016 - 01/2016
2	Ventilator-Associated Pneumonia 10/2015 - 10/2014
1	Autoimmune Diseases (Autoimmune Disease) 01/2022
1	Dysbiosis 12/2021
1	Leukopenia 06/2021
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2021
1	Asthma (Bronchial Asthma) 01/2021
1	Hepatitis 01/2021
1	Chronic Hepatitis (Chronic Active Hepatitis) 01/2021
1	Acute Liver Failure (Fulminant Hepatic Failure) 01/2021
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2021
1	Renal Insufficiency (Renal Failure) 03/2020
1	Pneumonia (Pneumonitis) 01/2020
1	Tonsillitis 01/2020
1	Pharyngitis (Sore Throat) 01/2020

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 01/2022 - 03/2016
18	FluoroquinolonesIBA 12/2021 - 01/2011
16	Conjugate VaccinesIBA 11/2021 - 01/2016
14	AntigensIBA 12/2021 - 05/2008
10	Azithromycin (Zithromax)FDA LinkGeneric 10/2021 - 05/2015
10	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2021 - 12/2010
9	Pharmaceutical PreparationsIBA 01/2022 - 07/2011
9	tartrate-sensitive acid phosphataseIBA 10/2019 - 11/2015
7	Gatifloxacin (Zymar)FDA Link 06/2017 - 06/2011
6	Carbapenems (Carbapenem Antibiotics)IBA 11/2021 - 10/2014
6	Ofloxacin (Ofloxacine)FDA LinkGeneric 01/2021 - 12/2010
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2009
5	AntibodiesIBA 01/2019 - 01/2013
4	Immunoglobulin G (IgG)IBA 12/2021 - 01/2013
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2010
4	EnzymesIBA 12/2020 - 01/2013
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 10/2016
4	Immunoglobulin M (IgM)IBA 01/2017 - 02/2012
3	Typhoid-Paratyphoid Vaccines (Typhoid Vaccines)FDA Link 12/2021 - 01/2018
3	TCVSIBA 10/2021 - 10/2019
3	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2021 - 05/2016
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2013
2	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 09/2007
2	Insulin (Novolin)FDA Link 01/2019 - 09/2007
2	Drinking WaterIBA 01/2019 - 11/2010
2	Third Generation CephalosporinsIBA 10/2018 - 05/2016
2	16S Ribosomal RNAIBA 01/2018 - 01/2016
2	Lidocaine (Xylocaine)FDA LinkGeneric 02/2017 - 01/2017
2	ProteomeIBA 01/2017 - 01/2013
2	Colistin (Coly-Mycin)FDA Link 01/2016 - 10/2015
2	Nalidixic Acid FDA Link 01/2013 - 08/2011
2	Chloramphenicol (Chloromycetin)FDA Link 12/2012 - 06/2011
1	carbapenemaseIBA 06/2022
1	Virulence Factors (Pathogenicity Factors)IBA 06/2022
1	Rituximab (Mabthera)FDA Link 01/2022
1	Bile Acids and Salts (Bile Acids)IBA 01/2022
1	L 084IBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	AllergensIBA 12/2021
1	tebipenemIBA 11/2021
1	C-Reactive ProteinIBA 06/2021
1	EpitopesIBA 01/2021
1	Ribavirin (Virazole)FDA LinkGeneric 01/2021
1	Cefixime (Suprax)FDA Link 01/2021
1	AminoglycosidesIBA 12/2020
1	Dengue VaccinesIBA 07/2020
1	Polymyxins (Polymyxin)IBA 03/2020
1	Monoclonal AntibodiesIBA 01/2020

Therapy/Procedure

16	Therapeutics 01/2022 - 06/2010
2	Catheters 06/2021 - 01/2018
2	Critical Care (Surgical Intensive Care) 01/2021 - 01/2021
2	Injections 02/2017 - 01/2017
2	Radiotherapy 01/2014 - 10/2010
2	Duration of Therapy 06/2011 - 06/2011
2	Gastric Bypass (Roux-en-Y Gastric Bypass) 09/2007 - 05/2003
1	Mechanical Ventilators (Ventilator) 11/2021
1	Artificial Respiration (Mechanical Ventilation) 06/2021
1	Blood Transfusion (Blood Transfusions) 06/2021
1	Cannula 06/2021
1	Long-Term Care 10/2020
1	Urinary Catheters 03/2020
1	Operative Surgical Procedures 03/2020
1	Patient Admission (Patient Admissions) 01/2020
1	Personal Protective Equipment 12/2019